STOCK TITAN

ALX Oncology Q3 2026 net loss narrows to $21.8M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. (ALXO) reported third-quarter 2026 results and clinical updates. Cash, cash equivalents and investments were $147.2 million as of September 30, 2026; the company said these resources were sufficient to fund planned operations through the first half of 2028. Third-quarter GAAP net loss was $21.8 million, or $0.15 per share, versus $22.1 million, or $0.41 per share, in the prior-year quarter. R&D expense was $17.5 million versus $17.4 million, and G&A expense was $5.5 million versus $5.1 million.

ALX Oncology expects safety and early efficacy data from the ALX2004 Phase 1 dose-escalation study in December 2026 and plans a webinar discussing results from 35 enrolled patients. Topline data from approximately 120 patients in the Phase 2 ASPEN-09-Breast trial are expected in the second half of 2027. Nine-month GAAP net loss was $57.7 million, compared with $78.8 million in 2025.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointNine-month GAAP net loss fell to $57.7 million from $78.8 million.

Negative

  • None.

Filing Explained

Quarterly GAAP net loss was $21,826 thousand versus $22,144 thousand, while weighted-average shares used to calculate loss per share rose from 53,577,066 to 140,904,752; the company says the higher share count primarily explains the lower loss per share.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash, cash equivalents and investments $147.2 million As of September 30, 2026; stated to be sufficient to fund planned operations through the first half of 2028.
R&D expenses $17.5 million Three months ended September 30, 2026; compared with $17.4 million in the prior-year period.
G&A expenses $5.5 million Three months ended September 30, 2026; compared with $5.1 million in the prior-year period.
GAAP net loss $21.8 million Three months ended September 30, 2026; compared with $22.1 million in the prior-year period.
GAAP net loss per share ($0.15) per basic and diluted share Three months ended September 30, 2026; compared with ($0.41) in the prior-year period.
Non-GAAP net loss $18.9 million Three months ended September 30, 2026; compared with $19.6 million in the prior-year period.
Nine-month GAAP net loss $57.7 million Nine months ended September 30, 2026; compared with $78.8 million in 2025.
ASPEN-09-Breast topline data population Approximately 120 patients Topline data expected in the second half of 2027.
CD47 checkpoint inhibitor medical
"evorpacept, is a highly differentiated potential best- and first-in-class CD47 checkpoint inhibitor"
biomarker-driven development strategy medical
"further validate the Company's biomarker-driven development strategy"
antibody-drug conjugate (ADC) medical
"EGFR-targeted antibody-drug conjugate (ADC)"
An antibody-drug conjugate (ADC) is a targeted medical treatment that combines an antibody, which acts like a guided missile seeking out specific cells, with a powerful drug to destroy those cells. It is designed to deliver medication directly to diseased cells, minimizing damage to healthy tissue. For investors, ADCs represent innovative therapies with potential for high growth, especially if they prove effective in treating difficult-to-cure conditions.
topoisomerase I inhibitor (Top1i) payload medical
"proprietary topoisomerase I inhibitor (Top1i) payload"
Fast Track designation regulatory
"FDA has granted Fast Track designation to evorpacept"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Orphan Drug Designation regulatory
"FDA and European Commission have granted Orphan Drug Designation"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
GAAP net loss $21.8 million loss Compared with $22.1 million loss in the third quarter of 2025.
GAAP net loss per share ($0.15) per basic and diluted share Compared with ($0.41) per share in the third quarter of 2025.
R&D expenses $17.5 million Compared with $17.4 million in the third quarter of 2025.
G&A expenses $5.5 million Compared with $5.1 million in the third quarter of 2025.
Non-GAAP net loss $18.9 million loss Compared with $19.6 million loss in the third quarter of 2025.
Guidance

The company believes its cash, cash equivalents and investments are sufficient to fund planned operations through the first half of 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was ALXO’s net loss in the third quarter of 2026?

ALX Oncology reported a third-quarter GAAP net loss of $21.8 million, or $0.15 per basic and diluted share, compared with a $22.1 million loss, or $0.41 per share, in the third quarter of 2025. Non-GAAP net loss was $18.9 million, compared with $19.6 million a year earlier.

When does ALXO expect results from its ALX2004 and ASPEN-09-Breast trials?

ALX Oncology expects safety and early efficacy data from its ALX2004 Phase 1 dose-escalation study in December 2026, covering 35 patients enrolled to date. Topline data from approximately 120 patients in the Phase 2 ASPEN-09-Breast trial are expected in the second half of 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000181018200018101822026-11-162026-11-16

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

ALX ONCOLOGY HOLDINGS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39386

85-0642577

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

323 Allerton Avenue,

South San Francisco, California

94080

(Address of Principal Executive Offices)

(Zip Code)

 

650-466-7125

(Registrant’s Telephone Number, Including Area Code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

ALXO

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 


 

Item 2.02 Results of Operations and Financial Condition.

On November 16, 2026, ALX Oncology Holdings Inc. (the “Company”), issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly stated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

 

Description

 

 

 

99.1

Press Release dated November 16, 2026

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ALX ONCOLOGY HOLDINGS INC.

 

 

 

 

Date: November 16, 2026

By:

/s/ Harish Shantharam

Harish Shantharam

Chief Financial Officer

 

 


 

img62044099_0.gif

Exhibit 99.1

 

ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update

 

Expect to report safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in EGFR-expressing solid tumors and plan to host a KOL webinar to review the results in December 2026

 

Topline data from 120 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer expected in 2H 2027

 

SOUTH SAN FRANCISCO, Calif., November 16, 2026 – ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

 

“Throughout the third quarter, we continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials,” said Jason Lettmann, Chief Executive Officer of ALX Oncology. “The recent publication of ASPEN-06 results in Nature Medicine further reinforces the promise of evorpacept and our biomarker-driven development strategy. Enrollment in ASPEN-09-Breast remains robust, and we now expect to report topline data from approximately 120 patients in the second half of 2027. ALX2004 continues to advance as a differentiated EGFR-targeted ADC with the potential to address a broad range of EGFR-expressing solid tumors, and we look forward to reporting safety and early efficacy data from the ongoing Phase 1 study in December. With multiple clinical catalysts ahead, a differentiated pipeline, and a strong commitment to disciplined execution, we believe ALX Oncology is well positioned to create long-term value for both patients and shareholders.”

 

ALX Oncology Q3 2026 Highlights and Recent Developments

 

Evorpacept

 

•
In September, ALX Oncology announced publication of data from the randomized Phase 2 ASPEN-06 trial in Nature Medicine, highlighting encouraging efficacy and durable clinical benefit for evorpacept in HER2-positive gastric and gastroesophageal junction cancers. The study demonstrated improved response rates versus the control arm, with the greatest benefit observed in patients whose tumors retained HER2 expression and exhibited high CD47 expression. These findings support CD47 as a potential predictive biomarker, further validate the Company's biomarker-driven development strategy, and reinforce continued advancement of the ongoing Phase 2 ASPEN-09-Breast trial evaluating evorpacept in patients with HER2-positive metastatic breast cancer.
•
Enrollment in the ongoing ASPEN-09-Breast Phase 2 trial evaluating evorpacept in combination with trastuzumab and chemotherapy remains on track, with topline data from 120 patients expected in the second half of 2027.

 

ALX2004

 

•
Dose-escalation safety and early efficacy data from the ongoing ALX2004 Phase 1 clinical trial (NCT07085091), a first-in-human, open-label, multicenter trial evaluating ALX2004 in patients with advanced or metastatic select EGFR-expressing solid tumors,

1


 

are expected in December 2026, and the Company plans to host a KOL webinar to review the safety and efficacy results from 35 patients enrolled to date.

 

Third Quarter 2026 Financial Results

 

•
Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of September 30, 2026, were $147.2 million. The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations through the first half of 2028.
•
Research and Development (“R&D”) Expenses: R&D expenses consist primarily of clinical and development costs related to the development of the Company’s current product candidates, evorpacept and ALX2004, and R&D personnel-related expenses, including stock-based compensation. R&D expenses for the three months ended September 30, 2026 were $17.5 million compared to $17.4 million for the prior-year period, remaining substantially unchanged from prior-year period. This was attributable to an increase of $1.3 million in clinical and development costs for increased site activations and patient enrollment in the evorpacept ASPEN-09 Phase 2 trial and ALX2004 Phase 1 study, $1.0 million in personnel and related costs due to headcount growth, an increase of $0.2 million in preclinical costs, and an increase of $0.2 million in stock-based compensation expense offset by a decrease of $2.6 million in other research costs primarily due to a $2.5 million development milestone met in prior period that does not exist in the current period.
•
General and Administrative (“G&A”) Expenses: G&A expenses consist primarily of administrative personnel-related expenses, including stock-based compensation and other costs such as legal and other professional fees, patent filing and maintenance fees, and insurance. G&A expenses for the three months ended September 30, 2026 were $5.5 million compared to $5.1 million for the prior year period, or an increase of $0.4 million. This increase was primarily attributable to an increase of $0.6 million in personnel and related costs driven by headcount growth and an increase of $0.2 million in stock-based compensation expense offset by a decrease of $0.4 million in corporate legal, patent legal, and corporate consulting costs.
•
Net loss: GAAP net loss was ($21.8) million for the three months ended September 30, 2026, or ($0.15) per basic and diluted share, as compared to a GAAP net loss of ($22.1) million for the three months ended September 30, 2025, or ($0.41) per basic and diluted share. The decrease in net loss per share was primarily attributable to the increase in weighted-average shares of common stock outstanding in 2026. Non-GAAP net loss was ($18.9) million for the three months ended September 30, 2026, as compared to a non-GAAP net loss of ($19.6) million for the three months ended September 30, 2025. A reconciliation of GAAP to non-GAAP financial results can be found at the end of this news release.

 

About ALX2004

ALX2004 is an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) engineered with the Company’s proprietary topoisomerase I inhibitor (Top1i) payload and linker platform. Designed to maximize the therapeutic window, ALX2004 combines an affinity-tuned EGFR antibody with a binding epitope distinct from approved EGFR antibodies, a proprietary Top1i payload engineered for enhanced bystander activity and improved linker stability, enabling efficient on-target payload delivery while reducing toxicity. ALX2004 is currently being evaluated in a Phase 1 clinical trial (NCT07085091), a first-in-human, open-label, multicenter study in patients with advanced or metastatic EGFR-expressing solid tumors.

2


 

 

About Evorpacept

ALX Oncology's lead therapeutic candidate, evorpacept, is a highly differentiated potential best- and first-in-class CD47 checkpoint inhibitor and one of the most advanced checkpoint inhibitors to target and activate the innate immune system. Evorpacept was intentionally designed to maximize the clinical potential of blocking CD47, while reducing the toxicities associated with previous approaches to CD47 blockade. In clinical studies across a wide spectrum of tumor types in more than 750 patients to date, evorpacept has demonstrated potential to enhance the therapeutic activity of many of the most important cancer therapies available today, contributing an additional, differentiated immuno-oncology mechanism. Based on this potential, ALX Oncology is advancing a robust clinical program evaluating evorpacept in a wide range of cancer indications, prioritizing its combination with anti-cancer antibodies in breast, gastric and colon cancers. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to evorpacept for the second-line treatment of patients with HER2-positive gastric or GEJ carcinoma. Additionally, both the FDA and European Commission have granted Orphan Drug Designation for this indication.

 

About ALX Oncology

ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn and X.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of regulatory and commercial success, plans and objectives of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (SEC), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

3


 

ALX ONCOLOGY HOLDINGS INC.

Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share amounts)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

17,463

 

 

$

17,441

 

 

$

44,207

 

 

$

59,351

 

General and administrative

 

 

5,483

 

 

 

5,091

 

 

 

15,976

 

 

 

18,474

 

Lease termination (gain) and impairment charge

 

 

—

 

 

 

—

 

 

 

(238

)

 

 

3,175

 

Total operating expenses

 

 

22,946

 

 

 

22,532

 

 

 

59,945

 

 

 

81,000

 

Loss from operations

 

 

(22,946

)

 

 

(22,532

)

 

 

(59,945

)

 

 

(81,000

)

Interest income

 

 

1,379

 

 

 

802

 

 

 

4,069

 

 

 

3,391

 

Interest expense

 

 

(225

)

 

 

(408

)

 

 

(841

)

 

 

(1,219

)

Other expense, net

 

 

(34

)

 

 

(6

)

 

 

(103

)

 

 

(19

)

Loss on debt extinguishment

 

 

—

 

 

 

—

 

 

 

(904

)

 

 

—

 

Net loss

 

$

(21,826

)

 

$

(22,144

)

 

$

(57,724

)

 

$

(78,847

)

Net loss per share, basic and diluted

 

$

(0.15

)

 

$

(0.41

)

 

$

(0.45

)

 

$

(1.48

)

Weighted-average shares of common stock used to compute net loss per shares, basic and diluted

 

 

140,904,752

 

 

 

53,577,066

 

 

 

127,058,949

 

 

 

53,452,319

 

 

Consolidated Balance Sheet Data

(unaudited)

(in thousands)

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Cash, cash equivalents and investments

 

$

147,206

 

 

$

48,284

 

Total assets

 

$

154,671

 

 

$

59,046

 

Total liabilities

 

$

28,818

 

 

$

33,065

 

Accumulated deficit

 

$

(780,541

)

 

$

(722,817

)

Total stockholders’ equity

 

$

125,853

 

 

$

25,981

 

 

4


 

GAAP to Non-GAAP Reconciliation

(unaudited)

(in thousands)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

GAAP net loss, as reported

 

$

(21,826

)

 

$

(22,144

)

 

$

(57,724

)

 

$

(78,847

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

2,893

 

 

 

2,521

 

 

 

8,085

 

 

 

9,873

 

Accretion of term loan discount and issuance costs

 

 

34

 

 

 

72

 

 

 

168

 

 

 

208

 

Lease termination (gain) and impairment charge

 

 

—

 

 

 

—

 

 

 

(238

)

 

 

3,175

 

Loss on disposal of fixed assets

 

 

—

 

 

 

—

 

 

 

246

 

 

 

—

 

Loss on early debt extinguishment

 

 

—

 

 

 

—

 

 

 

904

 

 

 

—

 

Total adjustments

 

 

2,927

 

 

 

2,593

 

 

 

9,165

 

 

 

13,256

 

Non-GAAP net loss

 

$

(18,899

)

 

$

(19,551

)

 

$

(48,559

)

 

$

(65,591

)

 

 

Use of Non-GAAP Financial Measures

 

We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered “non-GAAP” financial measures under applicable SEC rules. We believe that the disclosure of these non-GAAP financial measures provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss, and are not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.

 

“Non-GAAP net loss” is not based on any standardized methodology prescribed by GAAP and represents GAAP net loss adjusted to exclude stock-based compensation expense, accretion of term loan discount and issuance costs, lease termination gain and impairment charge, loss on disposal of fixed assets and loss on early debt extinguishment. Non-GAAP financial measures used by ALX Oncology may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

 

Investor Relations Contact:

Kevin Lui

Director, Investor Relations

Precision AQ

kevin.lui@precisionaq.com

 

Media Contact:

Genevieve Britton

Senior Director, Public Relations

Precision AQ

genevieve.britton@precisionaq.com

5


Filing Exhibits & Attachments

2 documents

Keep reading